Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 7/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | APEX1 | P27695 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.36 |
| ▸ | HTT | P42858 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MITF | O75030 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.36 |
| ▸ | MC4R | P32245 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1322135 | 1.00 | KMT2A (0.56) | KMT2AALDH1A1POLBHCAR1GAA | |
| SCHEMBL17537313 | 0.87 | KMT2A (0.51) | KMT2AALDH1A1POLBHCAR1GAA | |
| SCHEMBL1321811 | 0.85 | KMT2A (0.74) | KMT2AALDH1A1POLBHCAR1GAA | |
| SCHEMBL30910853 | 0.84 | KMT2A (0.57) | KMT2AALDH1A1POLBHCAR1GAA | |
| SCHEMBL30910852 | 0.84 | KMT2A (0.57) | KMT2AALDH1A1POLBHCAR1GAA | |
| SCHEMBL30910850 | 0.84 | KMT2A (0.57) | KMT2AALDH1A1POLBHCAR1GAA | |
| Resomelagon SCHEMBL30064288 | 0.81 | KMT2A (0.45) | KMT2AALDH1A1GAAMAPTMEN1 | |
| Resomelagon SCHEMBL30065234 | 0.81 | KMT2A (0.45) | KMT2AALDH1A1GAAMAPTMEN1 | |
| Resomelagon SCHEMBL29214577 | 0.81 | KMT2A (0.45) | KMT2AALDH1A1GAAMAPTMEN1 | |
| Resomelagon SCHEMBL12123977 | 0.81 | KMT2A (0.45) | KMT2AALDH1A1GAAMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2348016-B1 | Phenyl pyrrole aminoguanidine derivatives | SYNACT PHARMA APS (DK) | 2016-02-17 | — | — | EP | disclosed |
| CN-101466669-B | phenyl pyrrole aminoguanidine derivatives | Akshin pharmaceuticals (DK) | 2011-11-30 | — | — | CN | disclosed |
| US-8058306-B2 | Phenyl pyrrole aminoguanidine derivatives | ACTION PHARMA A/S (DK) | 2011-11-15 | — | — | US | disclosed |
| EP-2348016-A1 | Phenyl pyrrole aminoguanidine derivatives | Action Pharma A/S (DK) | 2011-07-27 | — | — | EP | disclosed |
| EP-2035373-B1 | PHENYL PYRROLE AMINOGUANIDINE DERIVATIVES | ACTION PHARMA AS (DK) | 2011-05-04 | — | — | EP | disclosed |
| US-20110082183-A1 | PHENYL PYRROLE AMINOGUANIDINE DERIVATIVES | ACTION PHARMA A/S (DK) | 2011-04-07 | — | — | US | disclosed |
| CN-101466669-A | Phenyl pyrrole aminoguanidine derivatives | ACTION PHARMA AS (DK) | 2009-06-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082183-A1 | PHENYL PYRROLE AMINOGUANIDINE DERIVATIVES | MC1R, MC5R, MC4R | KMT2A 3058/4885ALDH1A1 2301/4885POLB 2816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.